EBO-Ebos

[entrep]

cpanel got hacked which is a control panel for millions of websites worldwide.

[Shareguy]

Ebos is my largest NZX position by a long way after doubling down today. I just think it's great buying for long term holders.

Craigs thought the investor day had no real surprises and

Overnight Stephen Ridgewell has reiterated the Overweight recommendation on EBOS following its Investor Day in Sydney last week – the stock is simply "Too cheap to ignore" and we don't disagree – EBO has morphed from a defensive growth stock trading on a 23x PE to a yield stock trading on a 14x PE and 6% net yield following a +50% share price decline from its peak of $46.50 in March 2023 to its close yesterday at $21.80

[Basil]

10 year EPS CAGR of only 5% is not that impressive.  Consensus FY26 PE is 14.8 which seems about right for a company growing at such a modest rate, (noting from my earlier analysis and post their most recent 5 year EPS CAGR is only 3.3%).  I think it was egregiously overpriced at $40+ and has now come down to about fair value, mind you I thought that at $26 but did caution about buying more in the downtrend at that time.  Its not what I would call bargain / compelling value now but it may have bottomed looking at the chart so its better from a TA point of view now, that's for sure..  Quite frankly I think Craigs and others are probably pretty busy trying to cover their backside on why they got it so wrong calling it a BUY at $40+.  Referencing back to an egregiously overpriced point and saying its really cheap now compared to before, doesn't carry any objective weight with me and speaks to probable confirmation bias.  That's how I see it but good luck mate.  https://www.marketscreener.com/quote/stock/EBOS-GROUP-LIMITED-6494459/

[Shareguy]

 Last night's Australian Federal budget is for PBS spending of A$22.2bn in fiscal year 2027, up 9% on budget projections from a year ago. This is positive for EBOS and other pharmaceutical wholesalers, whose revenues are linked to PBS spend (though more closely linked to volume than value). While the budget projects only a 0.6% CAGR for PBS spending for the following three years, this is largely political gamesmanship so that the Government can announce "new" funding for new drugs which will be added to the PBS down the track. The more revealing projection is that, even despite this game playing, PBS funding growth is projected to be higher than previously (i.e. +0.6% pa next three years vs -0.1% in last year's budget

[Crackity]

Last night's Australian Federal budget is for PBS spending of A$22.2bn in fiscal year 2027, up 9% on budget projections from a year ago. This is positive for EBOS and other pharmaceutical wholesalers, whose revenues are linked to PBS spend (though more closely linked to volume than value). While the budget projects only a 0.6% CAGR for PBS spending for the following three years, this is largely political gamesmanship so that the Government can announce "new" funding for new drugs which will be added to the PBS down the track. The more revealing projection is that, even despite this game playing, PBS funding growth is projected to be higher than previously (i.e. +0.6% pa next three years vs -0.1% in last year's budget

But is it going to balance the loss ( maybe ) of the Chem Warehouse distribution in NZ? 🤔

[Shareguy]

But is it going to balance the loss ( maybe ) of the Chem Warehouse distribution in NZ? 🤔

Maybe. FB estimate that the CW NZ contract is a mid to high single-digit EBITDA contributor. I think that is the worry reflecting the weak sp.